NCT04665921 is a Phase 1 clinical trial of SGN-STNV in Carcinoma, Non-Small Cell Lung, sponsored by Seagen Inc..

Who is sponsoring NCT04665921?

NCT04665921 is sponsored by Seagen Inc..

What drugs are being tested in NCT04665921?

Interventions in NCT04665921: SGN-STNV.

What condition does NCT04665921 study?

NCT04665921 studies Carcinoma, Non-Small Cell Lung, HER2 Negative Breast Neoplasms, Ovarian Neoplasms, Uterine Cervical Neoplasms, Endometrial Neoplasms, Esophageal Neoplasms, Gastroesophageal Junction Carcinoma, Stomach Neoplasms, Colorectal Neoplasms, Exocrine Pancreatic Adenocarcinoma, Appendiceal Adenocarcinoma, Pseudomyxoma Peritonei.

Is NCT04665921 still recruiting?

NCT04665921 is currently terminated. Last updated 7 February 2025.

Last reviewed 2025-02-07 · How we verify

NCT04665921

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of SGN-STNV in Advanced Solid Tumors

Terminated Phase 1 Last updated 7 February 2025

What this trial tests

Phase 1 trial testing SGN-STNV in Carcinoma, Non-Small Cell Lung in 111 participants. Terminated before completion.

Timeline

18 January 2021

Primary endpoint
1 March 2024

1 March 2024

Quick facts

Lead sponsor	Seagen Inc.
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	111
Start date	18 January 2021
Primary completion	1 March 2024
Estimated completion	1 March 2024
Sites	18 locations across France, Italy, United Kingdom, Canada, United States, Spain

Drugs / interventions tested

SGN-STNV — full drug profile →

Conditions studied

Carcinoma, Non-Small Cell Lung — all drugs for Carcinoma, Non-Small Cell Lung →
HER2 Negative Breast Neoplasms — all drugs for HER2 Negative Breast Neoplasms →
Ovarian Neoplasms — all drugs for Ovarian Neoplasms →
Uterine Cervical Neoplasms — all drugs for Uterine Cervical Neoplasms →

Sponsor

Seagen Inc. — full company profile →

Who can join

18 and older, any sex, with Carcinoma, Non-Small Cell Lung or HER2 Negative Breast Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial will look at a drug called SGN-STNV to find out whether it is safe for patients with solid tumors. It will study SGN-STNV to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study how well SGN-STNV works to treat solid tumors. The study will have two parts. Part A of the study will find out how much SGN-STNV should be given to patients. Part B will use the dose found in Part A to find out how safe SGN-STNV is and if it works to treat certain types of solid tumors.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting cancer with antibody-drug conjugates: Promises and challenges.
Dean AQ, Luo S, Twomey JD, Zhang B. · · 2021 · cited 145× · PMID 34291723 · DOI 10.1080/19420862.2021.1951427
Anti-glycan monoclonal antibodies: Basic research and clinical applications.
Gillmann KM, Temme JS, Marglous S, Brown CE, et al · · 2023 · cited 25× · PMID 36905763 · DOI 10.1016/j.cbpa.2023.102281
Tumor glyco-immunology, glyco-immune checkpoints and immunotherapy.
Pinho SS, Macauley MS, Läubli H. · · 2025 · cited 7× · PMID 40533266 · DOI 10.1136/jitc-2025-012391
Glycan diversity in ovarian cancer: Unraveling the immune interplay and therapeutic prospects.
Wolters-Eisfeld G, Oliveira-Ferrer L. · · 2024 · cited 7× · PMID 39432076 · DOI 10.1007/s00281-024-01025-6
Decoding the Molecular Basis of the Specificity of an Anti-sTn Antibody.
Soares CO, Laugieri ME, Grosso AS, Natale M, et al · · 2025 · cited 6× · PMID 39886580 · DOI 10.1021/jacsau.4c00921
Detection of N-glycolyl-neuraminic acid-containing glycolipids in human skin.
Manni M, Mantuano NR, Zingg A, Kappos EA, et al · · 2023 · cited 4× · PMID 38094289 · DOI 10.3389/fimmu.2023.1291292

Verify or expand the search:

Other recruiting trials for Carcinoma, Non-Small Cell Lung

Currently open trials in the same condition.

NCT07227298 — Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer · Phase 1, PHASE2 · recruiting
NCT06868277 — A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic · Phase 3 · recruiting
NCT05358249 — Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation · Phase 1, PHASE2 · active not recruiting
NCT04389632 — A Study of Sigvotatug Vedotin in Advanced Solid Tumors · Phase 1 · recruiting

Other Seagen Inc. trials

Trials by the same sponsor.

NCT05244473 — A Safety Study of Brentuximab Vedotin in Participants With HIV · Phase 1 · withdrawn
NCT05229900 — A Study of SGN-ALPV in Advanced Solid Tumors · Phase 1 · terminated
NCT04993677 — A Study of SEA-CD40 Given With Other Drugs in Cancers · Phase 2 · completed
NCT04499924 — Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastro · Phase 2, PHASE3 · completed
NCT04254107 — A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer · Phase 1 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04665921 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Seagen Inc.
Last refreshed: 7 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04665921.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing